Artículos Científicos

DATE: 2018/04/10
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018. Epub 2018 Apr 5.
AUTHORS: European Association for the Study of the Liver. Electronic address:; European Association for the Study of the Liver.
PMID: 29628280
DATE: 2018/02/27
Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
Clin Drug Investig. 2018 Apr;38(4):387-388. doi: 10.1007/s40261-018-0625-5.
AUTHORS: Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.
PMID: 29480453
DATE: 2018/02/09
Effectiveness of a Specialized Brief Intervention for At-risk Drinkers in an Emergency Department: Short-term Results of a Randomized Controlled Trial
Acad Emerg Med. 2018 May;25(5):517-525. doi: 10.1111/acem.13384. Epub 2018 Apr 2.
AUTHORS: Bruguera P, Barrio P, Oliveras C, Braddick F, Gavotti C, Bruguera C, López-Pelayo H, Miquel L, Segura L, Colom J, Ortega L, Vieta E, Gual A.
PMID: 29418049
DATE: 2018/01/12
Alcohol, tobacco and health care costs: a population-wide cohort study (n = 606 947 patients) of current drinkers based on medical and administrative health records from Catalonia
Eur J Public Health. 2018 Aug 1;28(4):674-680. doi: 10.1093/eurpub/ckx236.
AUTHORS: Miquel L, Rehm J, Shield KD, Vela E, Bustins M, Segura L, Colom J, Anderson P, Gual A.
PMID: 29325000
DATE: 2018/01/02
Filling the gap between lab and clinical impact: An open randomized diagnostic trial comparing urinary ethylglucuronide and ethanol in alcohol dependent outpatients
Drug Alcohol Depend. 2018 Feb 1;183:225-230. doi: 10.1016/j.drugalcdep.2017.11.015. Epub 2017 Dec 27.
AUTHORS: Barrio P, Teixidor L, Ortega L, Lligoña A, Rico N, Bedini JL, Vieta E, Gual A.
PMID: 29291550
DATE: 2017/11/07
Barriers to implement screening for alcohol consumption in Spanish hypertensive patients
Fam Pract. 2018 May 23;35(3):295-301. doi: 10.1093/fampra/cmx107.
AUTHORS: Miquel L, López-Pelayo H, Nuño L, Arbesú JÁ, Zarco J, Manthey J, Rehm J, Gual A.
PMID: 29106526
DATE: 2017/10/29
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results
Clin Drug Investig. 2018 Feb;38(2):147-155. doi: 10.1007/s40261-017-0590-4.
AUTHORS: Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.
PMID: 29080208
DATE: 2017/05/12
Psychoactive constituents of cannabis and their clinical implications: a systematic review
Adicciones. 2018 Apr 15;30(2):140-151. doi: 10.20882/adicciones.858.
AUTHORS: Casajuana Köguel C, López-Pelayo H, Balcells-Olivero MM, Colom J, Gual A.
PMID: 28492950
DATE: 2017/02/08
Patients with alcohol use disorder: initial results from a prospective multicenter registry in the Spanish Network on Addiction Disorders. CohRTA Study
Adicciones. 2018 Jan 12;30(4):292-300. doi: 10.20882/adicciones.931.
AUTHORS: Sanvisens A, Zuluaga P, Rivas I, Rubio G, Gual A, Torrens M, Short A, Álvarez FJ, Tor J, Farré M, Rodríguez de Fonseca F, Muga R.
PMID: 28170055
DATE: 2016/10/18
Remediation therapy in patients with alcohol use disorders and neurocognitive disorders: A Pilot Study
Adicciones. 2018 Apr 15;30(2):93-100. doi: 10.20882/adicciones.757.
AUTHORS: Frías-Torres C, Moreno-España J, Ortega L, Barrio P, Gual A, Teixidor López L.
PMID: 27749971